Expression of leukemia/lymphoma-related factor (LRF/POKEMON) in human breast carcinoma and other cancers.
The POK family of proteins plays an important role in not only embryonic development and cell differentiation, but also in oncogenesis. Leukemia/lymphoma-related factor (LRF) belongs to the POK family of transcriptional repressors and is also known as POK erythroid myeloid ontogenic factor (POKEMON), which binds to short transcripts of HIV-1 (FBI-1) and TTF-1 interacting peptide (TIP21). Its oncogenic role is known only in lymphoma, non-small cell lung carcinoma, and malignant gliomas. The functional expression of LRF in human breast carcinoma has not yet been confirmed. The aim of this study was to investigate and compare the expression of LRF in human breast cancer tissues and other human tumors. The expression of LRF mRNA transcripts and protein was observed in twenty human benign and malignant breast biopsy tissues. Expression of LRF was observed in several formalin-fixed tissues by immunohistochemistry and immunofluorescence. All malignant breast tissues expressed mRNA transcripts and protein for LRF. However, 40% and 15% benign breast biopsy tissues expressed LRF mRNA transcripts and protein, respectively. The overall expression of LRF mRNA transcripts and total protein was significantly more in malignant breast tissues than the benign breast tissues. LRF expression was also observed in the nuclei of human colon, renal, lung, hepatocellular carcinomas and thymoma tumor cells. In general, a significantly higher expression of LRF was seen in malignant tissues than in the corresponding benign or normal tissue. Further studies are warranted to determine the malignant role of LRF in human breast carcinoma.
Aggarwal
Anshu
A
Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE, 68178, USA.
Hunter
William J
WJ
Aggarwal
Himanshu
H
Silva
Edibaldo D
ED
Davey
Mary S
MS
Murphy
Richard F
RF
Agrawal
Devendra K
DK
D001940:Breast / Q000378:metabolism / Q000473:pathology; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007938:Leukemia / Q000378:metabolism; D008223:Lymphoma / Q000378:metabolism; D009369:Neoplasms / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism*
D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D014157:Transcription Factors; C485514:ZBTB7A protein, human
Cancer Causes Control. 2008 Oct;19(8):819-28
18347922
Blood. 1999 Sep 15;94(6):1987-97
10477728
Pathol Int. 1997 Sep;47(9):600-7
9311010
Oncogene. 2003 Aug 28;22(36):5572-8
12944904
J Biol Chem. 2002 Jul 26;277(30):26761-8
12004059
Oncogene. 1999 Jan 14;18(2):365-75
9927193
Exp Mol Pathol. 2006 Oct;81(2):115-22
16919268
Science. 2007 May 11;316(5826):860-6
17495164
Lung Cancer. 2008 Oct;62(1):113-9
18550205
J Mol Med (Berl). 2008 May;86(5):597-608
18368381
Cancer Invest. 2000;18(4):356-65
10808372
J Biol Chem. 2004 Nov 5;279(45):47081-91
15337766
Cancer Res. 2005 Oct 1;65(19):8575-8
16204018
Oncogene. 1995 Dec 21;11(12):2689-97
8545127
Biochem Biophys Res Commun. 2006 Dec 8;351(1):1-6
17052694
Oncogene. 2003 Dec 4;22(55):8948-51
14654791
Nature. 2005 Jan 20;433(7023):278-85
15662416
N Engl J Med. 1994 Jul 7;331(1):10-5
8202095
Nucleic Acids Res. 1999 Mar 1;27(5):1251-62
9973611
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6947-52
8692924
J Biol Chem. 2003 Aug 1;278(31):29327-35
12750370
J Biol Chem. 2008 Nov 28;283(48):33199-210
18801742
Neurosurg Focus. 2005 Oct 15;19(4):E8
16241110
J Biol Chem. 2004 Mar 19;279(12):11711-8
14701838
Protein Sci. 2007 Feb;16(2):336-42
17189472
Oncogene. 2004 Jun 3;23(26):4567-76
15077196
Cell Physiol Biochem. 2007;20(1-4):167-80
17595526
Trends Cell Biol. 2006 Nov;16(11):578-87
16996269
J Biol Chem. 2005 Jul 29;280(30):27783-91
15917220